TNFRSF4 and neoplasm: In contrast, Zhang et al. reported that mAb binding to mouse OX40, which blocked ligand-binding and bound CRD2, or bound at the membrane-proximal domain (CRD4), provided stronger agonistic and anti-tumor activity than mAbs binding CRD1 and CRD3 [25].